- Motley Fool•15 hours ago
Gilead's bad moves this year were more omission than commission.
- Motley Fool•2 days ago
Bristol-Myers Squibb and Gilead Sciences are strong buys after a poor 2016. But Dynavax is probably best avoided after its steep drop-off this year.
- Reuters•2 days ago
U.S. President-elect Donald Trump's plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its ...
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
|Bid||71.74 x 100|
|Ask||73.31 x 100|
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.73|
|Dividend & Yield||1.88 (2.60%)|
|1y Target Est||N/A|